Venus Concept Secures 510(k) Approval for Venue NOVA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
FDA Clearance: Venus Concept has received 510(k) clearance from the U.S. FDA to market the Venus NOVA, a next-generation multi-application platform for non-invasive treatments.
Technology Integration: The Venus NOVA combines Adaptive Electrical Muscle Stimulation, Multi-Polar Radio Frequency with Pulsed Electromagnetic Fields, and Advanced VariPulse technology for comprehensive body contouring and skin treatments.
Treatment Benefits: The platform is designed to enhance muscle conditioning, skin treatments, and reduce wrinkles and cellulite.
Market Impact: This innovative technology aims to redefine non-invasive aesthetic treatments in the beauty and wellness industry.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like VERO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on VERO
About VERO
Venus Concept Inc. is a global medical technology company. The Company develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and nine direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical (ISRG) Reports Q4 Revenue of $2.87 Billion, Exceeding Expectations
- Earnings Beat: Intuitive Surgical reported Q4 revenue of approximately $2.87 billion and adjusted earnings of $2.53 per share, both exceeding analyst expectations, driven by year-over-year growth in procedure volume and robotic system placements, leading to a rise in after-hours trading.
- Dividend Increase: Kinder Morgan topped Q4 revenue expectations with about $4.51 billion and adjusted earnings of $0.39 per share, while announcing a 2% quarterly dividend increase to $0.2925 per share, despite slightly lowering its 2026 earnings outlook, reflecting cautious sentiment amid ongoing energy market dynamics.
- Expansion Plans: USA Rare Earth announced plans to establish a high-capacity metal and alloy production plant in Lacq, France, capable of producing about 3,750 metric tons per year through its subsidiary Less Common Metals, aimed at strengthening transatlantic supply chains and boosting investor optimism.
- Market Volatility: Despite subdued overall market performance, small-cap benchmarks reached new highs, indicating sustained investor demand for risk assets against a backdrop of easing geopolitical tensions, which positively influenced the performance of certain tech stocks.
Continue Reading
Venus Concept Inc. (VERO) to Voluntarily Delist from Nasdaq, Last Trading Day Expected February 6, 2026
- Voluntary Delisting Decision: Venus Concept announced its intention to voluntarily delist from Nasdaq and cease SEC reporting, with the board determining that ongoing compliance costs outweigh the benefits of remaining publicly listed, highlighting a focus on financial health.
- Financial Status Disclosure: As of September 30, 2025, the company reported inventories totaling $15.768 million and cash equivalents of $4.312 million, indicating liquidity management pressures that could impact future operations.
- Delisting Timeline: The company plans to file Form 25 with the SEC on January 30, 2026, with the last trading day expected on February 6, 2026, followed by a Form 15 filing on February 9, 2026, which will immediately suspend periodic reporting obligations, marking a significant step towards privatization.
- Management Statement: CEO Rajiv De Silva stated that this action is in the best interests of the company and its shareholders, indicating that the company will continue to work with Madryn Asset Management to support long-term financial success, reflecting strategic planning for future growth.
Continue Reading